LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on MLYS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda’s rating is based on several compelling factors regarding Mineralys Therapeutics, Inc. The company has demonstrated positive outcomes in its pivotal studies for lorundrostat, a treatment for patients with uncontrolled and resistant hypertension. These studies showed significant reductions in systolic blood pressure and confirmed the treatment’s safety and tolerability, which has impressed key opinion leaders in the field.
Additionally, Mineralys is well-positioned financially, with sufficient cash reserves expected to fund operations into 2027. The upcoming pre-NDA meeting with the FDA in Q4 2025 is a crucial step towards potential approval, which could further enhance the company’s prospects. The favorable risk-benefit profile of lorundrostat and the potential for it to move into earlier lines of treatment contribute to the positive outlook for Mineralys, supporting the Buy rating.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Vera Therapeutics, and Eledon Pharmaceuticals. According to TipRanks, Katkhuda has an average return of 13.1% and a 43.62% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.